HRT Financial’s Emergent Biosolutions EBS Stock Holding History

HRT Financial’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.29M	Sell	275,933 -35,851	-11%	-$371K	0.01%	1530
2025 Q4	$3.85M	Buy	+311,784	New	+$3.34M	0.01%	906
2025 Q2	–	Sell	-275,716	Closed	-$1.34M	–	2837
2025 Q1	$1.34M	Buy	+275,716	New	+$2.28M	0.01%	991
2024 Q3	–	Sell	-125,357	Closed	-$854K	–	2593
2024 Q2	$854K	Buy	+125,357	New	+$539K	﹤0.01%	1082
2023 Q4	–	Sell	-250,946	Closed	-$853K	–	2482
2023 Q3	$853K	Buy	+250,946	New	+$1.39M	0.01%	1097
2022 Q4	–	Sell	-32,142	Closed	-$674K	–	2616
2022 Q3	$674K	Buy	+32,142	New	+$894K	0.01%	1259
2022 Q2	–	Sell	-5,108	Closed	-$209K	–	3101
2022 Q1	$209K	Buy	+5,108	New	+$225K	﹤0.01%	2466
2019 Q2	–	Sell	-4,073	Closed	-$205K	–	788
2019 Q1	$205K	Buy	+4,073	New	+$240K	0.03%	389

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HRT Financial's EBS Position: Q1 2026 in Review

HRT Financial reduced its Emergent Biosolutions (EBS) stake by 11% in Q1 2026, selling an estimated $371K and leaving 275,933 shares worth $2.29M. The position accounts for 0.01% of the portfolio, ranked #1530.

HRT Financial first reported a position in EBS in Q1 2019 and has held it in 8 quarters since. The position peaked at $3.85M in Q4 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

HRT Financial held 275,933 shares of Emergent Biosolutions worth $2.29M as of Q1 2026.
HRT Financial sold 35,851 Emergent Biosolutions shares in Q1 2026, an estimated $371K.
Emergent Biosolutions made up 0.01% of HRT Financial's portfolio in Q1 2026, its #1530 holding.
HRT Financial first reported a position in Emergent Biosolutions in Q1 2019 and has held it in 8 quarters since.
HRT Financial's Emergent Biosolutions position peaked at $3.85M in Q4 2025.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.